The Journal of Experimental Medicine
Torrey Pines Biolabs
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published online 30 October 2006 doi:10.1084/jem.20060244
Rockefeller University Press, 0022-1007 $8.00
JEM, Volume 203, Number 12, 2577-2587
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 2988K)
Right arrow PPT slides of all figures
Right arrow Supplemental Material Index
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chan, J. R.
Right arrow Articles by Bowman, E. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chan, J. R.
Right arrow Articles by Bowman, E. P.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

ARTICLE

 IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2–dependent mechanisms with implications for psoriasis pathogenesis

Jason R. Chan1, Wendy Blumenschein2, Erin Murphy2, Caroline Diveu1, Maria Wiekowski3, Susan Abbondanzo3, Linda Lucian1, Richard Geissler4, Scott Brodie4, Alexa B. Kimball5, Daniel M. Gorman2, Kathleen Smith2, Rene de Waal Malefyt1, Robert A. Kastelein1, Terrill K. McClanahan2, and Edward P. Bowman1

1 Discovery Research and 2 Experimental Pathology and Pharmacology, Schering-Plough Biopharma (formerly DNAX Research, Inc.), Palo Alto, CA 94304
3 Immunology, Schering-Plough Research Institute, Kenilworth, NJ 07033
4 Drug Safety and Metabolism, Schering-Plough Research Institute, Lafayette, NJ 07848
5 Department of Dermatology, Stanford University School of Medicine, Stanford, CA 94305

CORRESPONDENCE Edward P. Bowman: eddie.bowman{at}spcorp.com

Aberrant cytokine expression has been proposed as an underlying cause of psoriasis, although it is unclear which cytokines play critical roles. Interleukin (IL)-23 is expressed in human psoriasis and may be a master regulator cytokine. Direct intradermal administration of IL-23 in mouse skin, but not IL-12, initiates a tumor necrosis factor–dependent, but IL-17A–independent, cascade of events resulting in erythema, mixed dermal infiltrate, and epidermal hyperplasia associated with parakeratosis. IL-23 induced IL-19 and IL-24 expression in mouse skin, and both genes were also elevated in human psoriasis. IL-23–dependent epidermal hyperplasia was observed in IL-19–/– and IL-24–/– mice, but was inhibited in IL-20R2–/– mice. These data implicate IL-23 in the pathogenesis of psoriasis and support IL-20R2 as a novel therapeutic target.

A.B. Kimball's present address is Massachusetts General and Brigham and Women's Hospitals, Harvard Medical School, Boston, MA 02114.

Abbreviations used: EM, electron micrograph; K16, keratin 16; KGF, keratinocyte growth factor 1.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS